Ebstrocel RDEB therapy advances with regulatory filings
INMB’s Ebstrocel (CORDStrom) is reported to be leading regulatory filings for RDEB, alongside late-stage progress in non-immunosuppressive inflammation therapies and ongoing manufacturing/regulatory milestones.